SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a strategic move to regain full control of its Ireland Fab 34 facility through a multi-billion dollar buyback from Apollo. The community is actively debating the implications of this capital-intensive play, with bulls interpreting the aggressive debt-funded repurchase as a sign of imminent major contract wins and long-term manufacturing strength.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending as shareholders voice intense frustration over the stock's lack of upward momentum, fueling renewed speculation regarding a potential buyout or urgent partnership deal. The community is actively debating the recent leadership changes in R&D and pressuring activist investor Shah Capital to force a strategic sale, while simultaneously highlighting the persistent suppression of share price by short interest and derivative market mechanics.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users weigh in on the President's latest aggressive rhetoric and shifting deadlines regarding the escalating conflict with Iran. Community discussion is heavily divided, focusing on the geopolitical risks of potential infrastructure strikes, the broader economic impact on global energy markets, and the controversy surrounding the administration's unconventional communication style.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following a strategic partnership with Ukraine's Spetstechnoexport to advance multi-domain uncrewed systems and the acquisition of Apium Swarm Robotics, fueling community excitement around the company's expanding defense capabilities. Investors are actively debating the stock's potential as a key player in the drone sector, balancing enthusiasm for new NATO and defense contracts against concerns over share dilution and the need for more concrete revenue guidance.

Applied Digital Corporation

Applied Digital is experiencing a significant surge in investor interest and stock price momentum driven by a combination of strong institutional backing, positive credit developments for its data center operations, and anticipation of upcoming earnings. Community members are actively discussing the company's progress on hyperscaler leases and its potential for a short squeeze, while balancing broader market concerns regarding geopolitical tensions and energy sector stability.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing a massive surge in investor interest driven by a strategic development agreement with Tower Semiconductor, which aims to integrate its high-speed polymer modulators into a silicon photonics platform for AI and data center applications. The community is actively debating the stock's long-term potential as a critical AI infrastructure play versus concerns over its pre-revenue status and historical volatility, with many users focused on whether the current momentum will lead to a broader industry shift or if the stock is vulnerable to a classic pump-and-dump cycle.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is maintaining strong momentum as the community rallies around its unique 'culture-first' brand identity ahead of key industry events. Investors are actively discussing its long-term potential, citing consistent organic growth and a commitment to advocacy that resonates with supporters beyond traditional market metrics.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a major focus for traders as the market weighs the impact of newly launched spot ETFs against broader sector volatility. The community remains deeply divided, with bulls pointing to the token's role in institutional RWA tokenization and potential regulatory clarity, while bears express frustration over price underperformance and the asset's tendency to follow broader market dumps.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is currently generating significant investor interest as it rides the momentum of the booming space sector, fueled by anticipation of a potential SpaceX IPO and increased demand for defense-related geospatial intelligence. The community is actively discussing the stock's long-term growth potential and recent technical price action, while monitoring key catalysts like upcoming industry symposiums, government contract developments, and the company's recent expansion of its satellite constellations.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

The community is closely watching STRC as its recent stabilization near par fuels high-conviction discussions about its role as a liquidity engine for aggressive Bitcoin accumulation. Investors are weighing the appeal of its double-digit monthly dividend and perceived stability against concerns regarding the long-term sustainability of the preferred equity flywheel and potential dilution risks for common shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merus&nbsp;NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades.<a href="https://stocktwits.com/symbol/MRUS">Shares of Merus</a> jumped 36% to close at $93.70 on Monday, before edging up 0.1%, in after-hours trading.Needham analyst Ami Fadia downgraded Merus to ‘Hold’ from ‘Buy’ without a price target after the company entered into the agreement. Citi downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $97 from $101, saying the possibility of a competing bid is very low.Wells Fargo analyst Eva Fortea Verdejo lowered her rating to ‘Equal Weight’ from ‘Overweight’ and raised the price target to $97 from $95. Canaccord downgraded Merus to ‘Hold’ from ‘Buy’ with a price target of $97, while William Blair cut its rating to ‘Market Perform’ from ‘Outperform’.Truist moved Merus to ‘Hold’ from ‘Buy’ and raised the price target to $97 from $88, saying the deal terms are “favorable, all things considered.”LifeSci Capital analyst Charles Zhu downgraded Merus to ‘Market Perform’ from ‘Outperform’ with a price target of $97. Guggenheim analyst Michael Schmidt downgraded the stock to ‘Neutral’ from ‘Buy’ and cut the target to $97 from $109.H.C. Wainwright downgraded Merus to ‘Neutral’ from ‘Buy’ and reduced its price target to $97 from $135, saying Merus’ full value is priced into the deal.The transaction, unanimously approved by both companies’ boards, gives Genmab full ownership of petosemtamab, Merus’ late-stage antibody therapy for head and neck cancer, which has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration.On Stocktwits, retail sentiment for Merus was ‘extremely bullish’ amid a 3,800% surge in 24-hour message volume.Some users congratulated Merus shareholders on the buyout, saying the acquisition marked a rewarding moment for long-term investors who held through difficult periods.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/630422083</stembedurl><stembedurl>https://stocktwits.com/Following_the_trend/message/630325826</stembedurl>Another user noted that the deal underscored the potential for other biotech firms to be acquired at higher valuations, citing that Merus was acquired by Genmab for $8 billion, despite its focus on the relatively smaller head and neck cancer market.<stembedurl>https://stocktwits.com/Power2k/message/630394868</stembedurl><a href="https://stocktwits.com/symbol/MRUS">Merus’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merus logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Equity

Retail chatter around Merus spiked late on Sunday after a report said Denmark’s Genmab is reportedly in advanced talks to acquire the Dutch biotech, which is developing a potential treatment for head and neck cancer.<a href="https://stocktwits.com/symbol/MRUS">Merus’ U.S.-listed stock</a> closed at $68.89 on Friday, up 1.2%, and surged over 19% to $82.03 in overnight trading.Merus has reportedly received multiple takeover offers from large pharmaceutical companies in recent weeks and could announce a deal within days, although there is no certainty that the talks will result in a transaction, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-28/genmab-is-said-in-talks-to-buy-cancer-drugmaker-merus?srnd=homepage-americas&amp;sref=8QBk7toa">reported</a>, citing people familiar with the matter.If finalized, the deal would be Genmab’s largest acquisition to date, Bloomberg reported. Genmab has a market capitalization of about 118 billion kroner ($18.5 billion), while Merus is valued at around $5.2 billion on the Nasdaq.Merus’ shares have risen sharply since May, when the company said its experimental drug petosemtamab was more effective than the current standard of care in shrinking tumors in head-and-neck cancer patients when combined with Keytruda. Bloomberg Intelligence has forecast that the drug could become a blockbuster therapy and exceed $1 billion in sales by 2030.Merus is also testing petosemtamab in advanced colon cancer, a larger and more lucrative potential market. Its smaller rival, Bicara Therapeutics, is developing a treatment for the same condition but remains further behind in development.On Stocktwits, retail sentiment for Merus was ‘bullish’ amid ‘high’ message volume, placing the stock among the top ten trending equities on the platform. Meanwhile, Genmab drew ‘extremely bearish’ sentiment amid ‘high’ message volume.One user congratulated the company on the reported development, while another user asked about the potential buyout price, reflecting curiosity about the rumored deal’s details.<stembedurl>https://stocktwits.com/CrispDry/message/630278149</stembedurl><stembedurl>https://stocktwits.com/Fugazi_/message/630280727</stembedurl>Merus’ U.S.-listed stock has risen 63.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

GMXAY
GENMAB A/S/S ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GMXAY News

GMXAYGENMAB A/S/S ADR